Cancer no more

GEMMAai™ platform combines proprietary database with novel AI algorithms revealing the secrets of tumor biology.

our technology

We have discovered that the unexplored part of tumor genomes hides huge amounts of information.

Through the use of whole genome sequencing (WGS) and other omics data, we redefine how to transform data into understanding.

More data = better understanding

We have discovered that the unexplored part of tumor genomes hides huge amounts of information.

Through the use of whole genome sequencing (WGS) and other omics data, we redefine how to transform data into understanding.

More data = better understanding

Data processing

At the core of our data processing lie multiple analytical algorithms that compute total DNA sequence, gene expression, protein interactions, and mutational patterns. GEMMAai™ ensures uniform data processing and rigorous quality control in a scalable environment.

Genomic features

We use biological expertise and proprietary AI machinery to explore tumor biology and reveal genomic features. The over 90,000 custom genomic features, serve as an input into the AI machinery, built by the combined expertise of biologists and data scientists.

Genomic features are numerical representations of molecular tumor characteristics - the key to understand oncogenesis.

Understanding

GEMMAai™ is dedicated to developing hypothesis-driven oncological discoveries via in-depth understanding of tumor biology.

The AI-platform reveals top genomic features defining the molecular mechanisms of oncogenesis. Our AI tools include exploratory dashboards, representation learning, neural networks, and model explainability.

This understanding lead us to the discovery of new drug targets.

Drug discovery

GEMMAai™ led us to identify MNM177, as a first-in-class drug, targeted at replication stress-high tumors.

New drug targets are validated via cell-based and in-vivo models, super-resolution microscopy, and high-throughput screening. Selected candidates are ready for pre-clinical trials.

We discovered
MNM177

Ineffective treatment no more

To fulfill our mission the right therapy for every cancer patient we developed a set of specialized assets.

Our assets